COMPASS Pathways: Data Demonstrating Long-Term Improvement i

More than half of the patients demonstrated remission of depression at 18 months, after a single dose of 25mg investigational COMP360 psilocybin with psychological supportOpen label phase 2 study, conducted

Related Keywords

United States , United Kingdom , London , City Of , American , Manish Agrawal , Guy Goodwin , Stephen Schultz , Amy Lawrence , Gewinn Nur , Exchange Commission , Drug Administration , Linkedin , Nasdaq , Sunstone Therapies , Annual Meeting , American Society , Clinical Oncology , Chief Medical Officer , Chief Executive Officer , Principal Investigator , Breakthrough Therapy , Innovative Licensing , Access Pathway , Securities Act , Private Securities Litigation Reform Act , Compass , Pathways , Data , Emonstrating , Song , Term , Improvement , Depression , Dancer , Patients , Following , Single , Nose , Omp360 , Silocybin , Therapy , Resented , Disco , 023 ,